Expand all sections

Semaglutide

Extended indication Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Semaglutide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension
Main indication Other metabolism and Endocrinology
Extended indication Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie uitbreiding zal slaan op het behandelen van obesitas.
Manufacturer Novo Nordisk
Portfolio holder Novo Nordisk
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2024
Expected Registration 2025
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References medicijnkosten.nl;
Additional remarks Gemiddelde kosten voor een tablet Rybelsus van 14 mg is €4,14 inclusief btw.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.